Department of Infectious Diseases, Sourô Sanou University Hospital, Bobo Dioulasso, Burkina Faso.
Clinical Research Department, Centre MURAZ, Bobo Dioulasso, Burkina Faso.
HIV Med. 2021 Feb;22(2):113-121. doi: 10.1111/hiv.12982. Epub 2020 Nov 3.
A risk score for long-term prediction of chronic kidney disease (CKD) in people living with HIV (PLHIV) has been developed using data from the D:A:D cohort. We assessed the performance of the D:A:D risk score in a cohort of PLHIV in West Africa.
Data from PLHIV starting antiretroviral treatment in four clinics in Burkina Faso, Côte d'Ivoire and Togo participating in the IeDEA West Africa collaboration were analysed. CKD was defined as two consecutive estimated glomerular filtration rates (eGFRs) of ≤ 60 mL/min/1.73 m . The D:A:D score (short version) was calculated using age, gender, nadir CD4 and baseline eGFR and was categorized into low, medium, and high-risk groups.
In 14 930 participants (70% female, median age = 38 years; median nadir CD4 count = 183 cells/µL) followed for a median duration of 5.7 years, 660 (4.4%) progressed to CKD, with an incidence [95% confidence interval (CI)] of 7.8 (7.2-8.4) per 1000 person-years (PY). CKD incidence rates were 2.4 (2.0-2.8), 8.1 (6.8-9.6) and, 30.9 (28.0-34.1) per 1000 PY in the low-, medium- and high-risk groups, respectively. In the high-risk group, 14.7% (95% CI: 13.3; 16.3) had progressed to CKD at 5 years. Discrimination was good [C-statistics = 0.81 (0.79-0.83)]. In all, 79.4% of people who progressed to CKD were classified in the medium- to high-risk group at baseline (sensitivity) and 66.5% of people classified in the low risk group at baseline did not progress to CKD (specificity).
These findings confirm the validity of the D:A:D score in identifying individuals at risk of developing CKD who could benefit from enhanced kidney monitoring in West African HIV clinics.
利用 D:A:D 队列的数据,为 HIV 感染者(PLHIV)开发了一种用于预测慢性肾脏病(CKD)长期风险的评分。我们评估了该评分在西非 PLHIV 队列中的表现。
对来自布基纳法索、科特迪瓦和多哥的四个诊所开始接受抗逆转录病毒治疗的 PLHIV 的 IeDEA 西非合作数据进行了分析。CKD 的定义为两次连续的估计肾小球滤过率(eGFR)均≤60 mL/min/1.73 m 。使用年龄、性别、最低 CD4 和基线 eGFR 计算 D:A:D 评分(短版本),并分为低危、中危和高危组。
在 14930 名参与者(70%为女性,中位年龄为 38 岁;中位最低 CD4 计数为 183 个/µL)中,中位随访时间为 5.7 年,有 660 名(4.4%)进展为 CKD,发病率[95%置信区间(CI)]为 7.8(7.2-8.4)/1000 人年(PY)。低危、中危和高危组的 CKD 发病率分别为 2.4(2.0-2.8)、8.1(6.8-9.6)和 30.9(28.0-34.1)/1000 PY。在高危组中,14.7%(95%CI:13.3;16.3)在 5 年内进展为 CKD。该评分具有良好的区分度[C 统计量=0.81(0.79-0.83)]。在所有进展为 CKD 的患者中,79.4%的患者在基线时被分类为中高危组(敏感性),而 66.5%的基线时被分类为低危组的患者未进展为 CKD(特异性)。
这些发现证实了 D:A:D 评分在识别可能受益于西非 HIV 诊所加强肾脏监测的 CKD 风险人群中的有效性。